Literature DB >> 33446629

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.

Michelle Y Wang1, Tao Li1, Yuan Ren1, Bijal D Shah2, Tint Lwin1, Jing Gao1, Kenneth H Shain1,2,3, Wei Zhang4, Xiaohong Zhao5, Jianguo Tao6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33446629      PMCID： PMC7809345          DOI： 10.1038/s41408-020-00402-2

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  15 in total

1.  An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.

Authors:  Ariosto Silva; Timothy Jacobson; Mark Meads; Allison Distler; Kenneth Shain
Journal:  J Vis Exp       Date:  2015-07-15       Impact factor: 1.355

Review 2.  BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Authors:  Delphine Merino; Gemma L Kelly; Guillaume Lessene; Andrew H Wei; Andrew W Roberts; Andreas Strasser
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

Review 3.  Pathology and classification of aggressive mature B-cell lymphomas.

Authors:  Elias Campo
Journal:  Hematol Oncol       Date:  2017-06       Impact factor: 5.271

4.  Up-regulation of Bcl-2 by CD147 Through ERK Activation Results in Abnormal Cell Survival in Human Endometriosis.

Authors:  Chaoqun Wang; Aihong Jin; Wenqing Huang; Lai Ling Tsang; Zhiming Cai; Xiaping Zhou; Hao Chen; Hsiao Chang Chan
Journal:  J Clin Endocrinol Metab       Date:  2015-05-21       Impact factor: 5.958

5.  A preclinical assay for chemosensitivity in multiple myeloma.

Authors:  Zayar P Khin; Maria L C Ribeiro; Timothy Jacobson; Lori Hazlehurst; Lia Perez; Rachid Baz; Kenneth Shain; Ariosto S Silva
Journal:  Cancer Res       Date:  2013-12-05       Impact factor: 12.701

6.  BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.

Authors:  Xiaohong Zhao; Yuan Ren; Matthew Lawlor; Bijal D Shah; Paul M C Park; Tint Lwin; Xuefeng Wang; Kenian Liu; Michelle Wang; Jing Gao; Tao Li; Mousheng Xu; Ariosto S Silva; Kaplan Lee; Tinghu Zhang; John M Koomen; Huijuan Jiang; Praneeth R Sudalagunta; Mark B Meads; Fengdong Cheng; Chengfeng Bi; Kai Fu; Huitao Fan; William S Dalton; Lynn C Moscinski; Kenneth H Shain; Eduardo M Sotomayor; Gang Greg Wang; Nathanael S Gray; John L Cleveland; Jun Qi; Jianguo Tao
Journal:  Cancer Cell       Date:  2019-05-13       Impact factor: 31.743

7.  Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.

Authors:  Huijuan Jiang; Tint Lwin; Xiaohong Zhao; Yuan Ren; Grace Li; Lynn Moscinski; Bijal Shah; Jianguo Tao
Journal:  Br J Haematol       Date:  2018-01-30       Impact factor: 6.998

8.  Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.

Authors:  David Sharon; Severine Cathelin; Sara Mirali; Justin M Di Trani; David J Yanofsky; Kristine A Keon; John L Rubinstein; Aaron D Schimmer; Troy Ketela; Steven M Chan
Journal:  Sci Transl Med       Date:  2019-10-30       Impact factor: 17.956

9.  BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway.

Authors:  Andrew Craxton; Kevin E Draves; Adriana Gruppi; Edward A Clark
Journal:  J Exp Med       Date:  2005-11-21       Impact factor: 14.307

10.  Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.

Authors:  Mathilde Rikje Willemijn de Jong; Myra Langendonk; Bart Reitsma; Marcel Nijland; Anke van den Berg; Emanuele Ammatuna; Lydia Visser; Tom van Meerten
Journal:  Int J Mol Sci       Date:  2019-11-30       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.